JP2020512389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512389A5 JP2020512389A5 JP2019554038A JP2019554038A JP2020512389A5 JP 2020512389 A5 JP2020512389 A5 JP 2020512389A5 JP 2019554038 A JP2019554038 A JP 2019554038A JP 2019554038 A JP2019554038 A JP 2019554038A JP 2020512389 A5 JP2020512389 A5 JP 2020512389A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- independently
- here
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 149
- 125000003118 aryl group Chemical group 0.000 claims description 86
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 81
- 125000001072 heteroaryl group Chemical group 0.000 claims description 76
- 229910052736 halogen Inorganic materials 0.000 claims description 73
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 54
- 239000012453 solvate Substances 0.000 claims description 38
- 208000015114 central nervous system disease Diseases 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 34
- 208000010877 cognitive disease Diseases 0.000 claims description 30
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 20
- 125000001931 aliphatic group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 15
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 150000004677 hydrates Chemical class 0.000 claims description 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 9
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 9
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 208000000172 Medulloblastoma Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 8
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 7
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 239000000164 antipsychotic agent Substances 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 6
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 6
- 229960004640 memantine Drugs 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000036626 Mental retardation Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 3
- 229960004372 aripiprazole Drugs 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229960003530 donepezil Drugs 0.000 claims description 3
- 229960003980 galantamine Drugs 0.000 claims description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 3
- 229960005017 olanzapine Drugs 0.000 claims description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 3
- 229960004136 rivastigmine Drugs 0.000 claims description 3
- 229960000607 ziprasidone Drugs 0.000 claims description 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 46
- 208000028698 Cognitive impairment Diseases 0.000 description 8
- -1 -C≡C- phenyl Chemical group 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 description 1
- 101000742736 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3G Proteins 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436272P | 2016-12-19 | 2016-12-19 | |
| US62/436,272 | 2016-12-19 | ||
| PCT/IB2017/001763 WO2018130869A1 (en) | 2016-12-19 | 2017-12-20 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| IBPCT/IB2017/001763 | 2017-12-20 | ||
| PCT/IB2017/001762 WO2018130868A1 (en) | 2016-12-19 | 2017-12-20 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512389A JP2020512389A (ja) | 2020-04-23 |
| JP2020512389A5 true JP2020512389A5 (enExample) | 2021-02-04 |
| JP7153938B2 JP7153938B2 (ja) | 2022-10-17 |
Family
ID=62557208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554038A Active JP7153938B2 (ja) | 2016-12-19 | 2017-12-20 | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180170941A1 (enExample) |
| EP (1) | EP3555100B1 (enExample) |
| JP (1) | JP7153938B2 (enExample) |
| CN (2) | CN110382501A (enExample) |
| AU (1) | AU2017393082B2 (enExample) |
| CA (1) | CA3047684A1 (enExample) |
| EA (1) | EA201991497A1 (enExample) |
| IL (1) | IL267451B2 (enExample) |
| MX (1) | MX388726B (enExample) |
| WO (2) | WO2018130868A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123897C (en) | 2013-12-20 | 2024-02-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN108026107B (zh) | 2015-06-19 | 2021-07-30 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| WO2019246300A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2020072675A1 (en) | 2018-10-02 | 2020-04-09 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) |
| US20230098667A1 (en) * | 2019-12-19 | 2023-03-30 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN116075302A (zh) * | 2020-07-10 | 2023-05-05 | 艾吉因生物股份有限公司 | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 |
| CA3185573A1 (en) * | 2020-07-10 | 2022-01-13 | Deepa GANDLA | Polymorphs of a gabaa .alpha.5 agonist and methods of using in the treatment of cognitive impairment |
| CN113413532B (zh) * | 2021-07-01 | 2022-03-01 | 曾迎春 | 基于虚拟现实的癌症相关认知障碍评估与康复训练系统 |
| US20240132513A1 (en) | 2022-08-19 | 2024-04-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| CH603545A5 (enExample) | 1972-04-20 | 1978-08-31 | Merz & Co | |
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
| ATE126512T1 (de) | 1989-05-19 | 1995-09-15 | Hoechst Roussel Pharma | N-(aryloxyalkyl)heteroarylpiperidine und - heteroarylpiperazine, verfahren zu ihrer herstellung und ihre verwendung als medikamente. |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (enExample) * | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| KR100330942B1 (ko) | 1994-03-02 | 2002-11-16 | 악조 노벨 엔.브이. | 설하또는협측투여용약학조성물 |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| EP1157989B1 (en) | 1999-03-03 | 2004-09-22 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) * | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| AU2003274353B2 (en) | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| CA2589836A1 (en) | 2002-11-22 | 2004-06-10 | The Johns Hopkins University | Target for therapy of cognitive impairment |
| ATE411015T1 (de) | 2003-10-22 | 2008-10-15 | Merz Pharma Gmbh & Co Kgaa | Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien |
| CA2581918A1 (en) * | 2004-10-12 | 2006-04-20 | Henner Knust | Imidazo(1,5-a)triazolo(1,5-d) benzodiazepine deratives for the treatment of cognitive disorders |
| RU2007114763A (ru) * | 2004-10-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Галогенозамещенные производные бензодиазепинов |
| ES2399439T3 (es) * | 2004-10-20 | 2013-04-01 | F. Hoffmann-La Roche Ag | Derivados de imidazo-benzodiazepina |
| BRPI0515800A (pt) * | 2004-12-14 | 2008-08-05 | Hoffmann La Roche | imidazo-benzodiazepinas tetracìclicas como moduladores de receptores de gaba |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010035118A1 (en) | 2008-09-25 | 2010-04-01 | Vive Nano, Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
| EP2523944A4 (en) | 2010-01-11 | 2013-06-19 | Mithridion Inc | COMPOUNDS AND COMPOSITIONS FOR IMPROVING COGNITION, METHODS OF MAKING THE SAME, AND METHODS OF TREATMENT |
| EP2635277B1 (en) * | 2010-11-05 | 2018-12-19 | F.Hoffmann-La Roche Ag | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| JP2013542266A (ja) * | 2010-11-15 | 2013-11-21 | エージンバイオ， インコーポレイテッド | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物、および方法 |
| US20150374705A1 (en) * | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| US20150224094A1 (en) | 2012-09-10 | 2015-08-13 | Ophirex, Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| CA3123897C (en) | 2013-12-20 | 2024-02-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN108026107B (zh) * | 2015-06-19 | 2021-07-30 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| WO2019246300A1 (en) * | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20230098667A1 (en) * | 2019-12-19 | 2023-03-30 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2017
- 2017-12-19 US US15/847,906 patent/US20180170941A1/en not_active Abandoned
- 2017-12-20 WO PCT/IB2017/001762 patent/WO2018130868A1/en not_active Ceased
- 2017-12-20 EP EP17891696.1A patent/EP3555100B1/en active Active
- 2017-12-20 CA CA3047684A patent/CA3047684A1/en active Pending
- 2017-12-20 AU AU2017393082A patent/AU2017393082B2/en active Active
- 2017-12-20 EA EA201991497A patent/EA201991497A1/ru unknown
- 2017-12-20 CN CN201780086584.0A patent/CN110382501A/zh active Pending
- 2017-12-20 WO PCT/IB2017/001763 patent/WO2018130869A1/en not_active Ceased
- 2017-12-20 IL IL267451A patent/IL267451B2/en unknown
- 2017-12-20 JP JP2019554038A patent/JP7153938B2/ja active Active
- 2017-12-20 CN CN202310213936.1A patent/CN116640143A/zh active Pending
- 2017-12-20 MX MX2019007338A patent/MX388726B/es unknown
-
2022
- 2022-09-02 US US17/902,374 patent/US20230134844A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512389A5 (enExample) | ||
| JP2018521034A5 (enExample) | ||
| JP2017500334A5 (enExample) | ||
| Diener et al. | A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome | |
| JP2014500295A5 (enExample) | ||
| HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
| JP2016517851A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2012517428A5 (enExample) | ||
| JP2014526469A5 (enExample) | ||
| JP2013518914A5 (enExample) | ||
| JP2023036007A5 (enExample) | ||
| MX388726B (es) | Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo. | |
| Tsutsumi et al. | The effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double‐blinded study | |
| MX2020013374A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. | |
| JP2018507191A5 (enExample) | ||
| JP2017503030A5 (enExample) | ||
| JPWO2019246300A5 (enExample) | ||
| JP2019516707A5 (enExample) | ||
| MX2023014436A (es) | Compuestos de 3-pirrolilsulfonamida como antagonistas de gpr17. | |
| Hasani et al. | Classification and toxicities of vascular disrupting agents | |
| IL299754A (en) | Combinations of gaba alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment | |
| HUP0301551A2 (hu) | 5-HT3 és idegi nikotinsav receptor antagonista 1-amino-alkil-ciklohexán származékok új alkalmazása | |
| JP2016515550A5 (enExample) | ||
| JP2017525684A5 (enExample) |